Drugs / NW-301D
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06956261 | May 2025 → Dec 2026 expected | soft tissue neoplasm | Peking University | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT06484556 | Jun 2024 → Jun 2026 overdue | — | Tao Zhang | Recruiting | No outcome recorded |
| Phase 1 | NCT06484790 | Apr 2024 → Apr 2026 overdue | soft tissue neoplasm | Ting Deng | Recruiting | No outcome recorded |
| Phase 1 | NCT06478251 | Feb 2024 → Jun 2026 overdue | — | TingBo Liang | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NW-301D | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06484556 ↗ |
| Modality | Cell therapy | “TCR-T cell targeting KRAS G12D mutation” NCT06478251 ↗ |
| Route | Intravenous | “single-dose intravenous infusion of NW-301V or NW-301D” NCT06478251 ↗ |
| Target | KRAS | “TCR-T cell targeting KRAS G12D mutation” NCT06478251 ↗ |